Appendices

APPENDIX 1. IDENTIFICATION OF SCIENTIFIC EVIDENCE

Literature search in MEDLINE

Research period	2013/04/01 - 2023/04/01
Indexing terms	Adenosarcoma, adjuvant chemotherapy, advanced disease, advanced stage, advanced tumour, anastrazole, aromatase inhibitor, bilateral salpingo-oophorectomy, biopsy, brachytherapy, brachytherapy boost, chemotherapy, cisplatin, clear margin, clinical staging, clinical trial, coaxial needle, complications, computed tomography, core-needle biopsy, cytoreduction, cytoreductive surgery, dacarbazine, definitive treatment, diagnosis, diagnostic work-up, diffusion weighted imaging, disease-free interval, DNA sequencing, docetaxel, doxorubicin, early stage, endocrine therapy, endometrial stromal sarcoma, endometrial stromal tumour, estrogen receptor, exemestane, external beam radiation therapy, external beam radiotherapy, FIGO, FIGO staging system, fluorescence in situ hybridization, follow-up, follow-up procedures, follow-up protocols, free interval, frozen section, fulvestrant, gemcitabine, gonadotrophin-releasing hormone, high-grade endometrial stromal sarcoma, high-grade tumour, high-grade variant, hormonal replacement therapy, hormonal therapy, hysterectomy, hysterectomy specimen, ifosfamide, image guided adaptive brachytherapy, image guided radiotherapy, imaging, imaging modalities, imaging procedure, imaging test, immunohistochemistry, intensity modulated radiotherapy, intensive care, intensive care unit, laparoscopic staging, laparoscopic surgery, laparoscopy, laparotomy, length of stay, leiomyosarcoma, letrozole, local clinical diagnostic work-up, local radiological diagnostic work-up, locally advanced disease, locally advanced stage, loccally advanced tumour, long-term survivorship, low-grade endometrial stromal sarcoma, low-grade tumour, low-grade variant, luteinizing hormone-releasing hormone, lymphadenectomy, lymph node, lymph node assessment, lymph node dissection, lymph node staging, lymphovascular infiltration, lymphovascular involvement, lymphovascular space invasion, lymphovascular space involvement, magnetic resonance imaging, management, margin status, medroxyprogesterone acetate, megestrol acetate, metastatic disease, minimally invasive technique, minimally invasive surgery, miscellaneous, molecular analysis, molecular testing, morcellation, mullerian adenosarcoma, mortality rate, mortality analysis, multidisciplinary board, multidisciplinary setting, multidisciplinary team, multivariate analysis, myometrial infiltration, myometrial invasion, neoadjuvant chemotherapy, neoadjuvant treatment, neurotrophic tropomyosin-receptor kinase, nodal involvement, open surgery, ovarian preservation, overall survival, oxaliplatin, paclitaxel, pain, palliative care, palliative chemotherapy, palliative management, palliative radiotherapy, palliative setting, palliative surgery, palliative systemic treatment, palliative treatment, para-aortic lymphadenectomy, para-aortic lymph node assessement, para-aortic lymph node dissection, parametrial resection, pathological analysis, pathological evaluation, pathological staging, pathology, pathology report, pathology report adequacy, patient-reported outcome, pazopanib, pelvic examination, pelvic lymph node assessement, pelvic lymph node dissection, pelvic lymphadenectomy, percutaneous biopsy, performance status, perioperative care, perivascular epithelioid cell tumour, physical examination, platinum, platinum-based chemotherapy, positron emission tomography, positron emission tomography/computed tomography, postoperative care, postoperative complications, preoperative brachytherapy, preoperative care, preoperative work-up, progestogen, progesterone receptor, progestin, prognosis, prognostic factor, progression-free survival, quality of health care, quality of life, radiation therapy, radiochemotherapy, radiological staging, radiotherapy, rare tumour, rare uterine cancer, rare uterine tumour, recurrence, recurrent disease, recurrent setting, recurrent tumour, relapse, relapse setting, reoperation, residual disease, residual tumour, restaging, risk factors, RNA sequencing, sarcoma, sarcomatous overgrowth, sensitivity, sentinel lymph node, sentinel lymph node dissection, sentinel lymph node procedure, sentinel node, serum biomarker, serum marker, smooth muscle tumor of uncertain malignant potential, specificity, specialized center, staging, staging procedures, stromal invasion, stromal involvement, supportive care, supportive management, supportive setting, supportive treatment, surgery, surgical lymph node assessment, surgical management, surgical margin, surgical outcome, surgical outcome criteria, surgical procedure, surgical resection, surgical staging, surveillance, survival, survival outcome, survival rate, survival analysis, survivorship, systematic lymphadenectomy, systematic para-aortic lymphadenectomy, systematic pelvic and para-aortic lymphadenectomy, systematic pelvic lymphadenectomy, systemic therapy, systemic treatment, tamoxifen, targeted therapy, terminal illness, terminally ill patient, total hysterectomy, trabectedin, treatment outcome, ultrasound, undifferentiated sarcoma, undifferentiated uterine sarcoma, uterine adenosarcoma, uterine leiomyosarcoma, uterine leiomyosarcoma, uterine preservation, uterine sarcoma, vascular space involvement, vascular endothelial growth factor.
Language	English
Study design	Priority was given to high-quality systematic reviews and meta-analyses but lower levels of evidence were also evaluated. The search strategy excluded editorials, letters and *in vitro* studies

APPENDIX 2. LIST OF THE 104 EXTERNAL REVIEWERS

Nuno Abecasis, surgical oncology (Portugal); **Dagmar Adamkova**, medical oncology (Czech Republic); **Kasimu Adoke**, pathology (Nigeria); **Roberto Altamirano**, gynecologic oncology, obstetrics & gynecology (Chile); **Igor Aluloski**, gynecologic oncology (North Macedonia); **Grazia Artioli**, medical oncology (Italy); **Giuseppe Badalamenti**, medical oncology (Italy); **Manel Barahona Orpinell**, gynecologic oncology (Spain); **Joost Bart**, pathology (Netherlands); **Mario Beiner**, gynecologic oncology (Israel); **Margarida Bernardino**, gynecologic oncology (Portugal); **Marcin Stanislaw Bobinski**, gynecologic oncology, obstetrics & gynecology (Poland); **Tjalling Bosse**, pathology (Netherlands); **Katharina Buser**, medical oncology (Switzerland); **Donato Callegaro-Filho**, medical oncology (Brazil); **Viktor Cassar**, gynecologic oncology (Malta); **Wen Yee Chay**, medical oncology (Singapore); **Abel Cordoba**, radiation oncology (France); **Ovidiu Florin Coza**, medical oncology, radiation oncology (Romania); **Bastian Czogalla**, gynecologic oncology (Germany); **Alessandro D'Amuri**, pathology (Italy); **Dominik Denschlag**, gynecologic oncology (Germany); **Palma Dileo**, medical oncology (United Kingdom); **Johannes Carl Athanasios Dimopoulos**, radiation oncology (Greece); **Santiago Domingo**, gynecologic oncology (Spain); **Florence Duffaud**, medical oncology (France); **Catherine Durdux**, radiation oncology (France); **Serkan Erkanli**, gynecologic oncology, obstetrics & gynecology (Türkiye); **Maria Del Pilar Estevez-Diz**, medical oncology (Brazil); **Henrik Falconer**, gynecologic oncology (Sweden); **Ana Felix**, pathology (Portugal); **Annamaria Ferrero**, gynecologic oncology (Italy); **Gwenael Ferron**, surgical oncology (France); **Alejandro Gallego**, medical oncology (Spain); **Silvia Gasperoni**, medical oncology (Italy); **Catherine Genestie**, pathology (France); **Christine Gennigens**, medical oncology (Belgium); **Eelke Gort**, medical oncology (Netherlands); **Daniela Greto**, radiation oncology (Italy); **Kenichi Harano**, medical oncology (Japan); **Sakari Hietanen**, gynecologic oncology (Finland); **Cathrine Holland**, gynecologic oncology (United Kingdom); **Toni Ibrahim**, medical oncology (Italy); **Ibon Jaunarena**, gynecologic oncology (Spain); **Pearly Khaw**, radiation oncology (Australia); **Mi Kyung Kim**, gynecologic oncology (Republic of Korea); **Gurkan Kiran**, gynecologic oncology (Türkiye); **Alexandra Timea Kirsch Mangu**, radiation oncology (Romania); **Takahiro Koyanagi**, gynecologic oncology (Japan); **Gunnar Kristensen**, gynecologic oncology (Norway); **Joel Laufer**, gynecologic oncology (Uruguay); **Kim-Seng Law**, gynecologic oncology (China); **Coriolan Lebreton**, medical oncology (France); **Mario Mendes Leitao Jr**, gynecologic oncology (United States of America); **Diana Lim**, pathology (Singapore); **Chien-Ting Liu**, gynecologic oncology, medical oncology (Taiwan); **Domenica Lorusso**, gynecologic oncology (Italy); **Giorgia Mangili**, gynecologic oncology, medical oncology (Italy); **Aranzazu Manzano**, medical oncology (Spain); **José María Mariconde**, gynecologic oncology (Argentina); **Gloria Marquina**, medical oncology (Spain); **Claudia Mateoiu**, pathology (Sweden); **Filomena Mazzeo**, medical oncology (Belgium); **Nadav Michaan**, gynecologic oncology (Israel); **Miloš Mlynček**, gynecologic oncology (Slovakia); **Philippe Morice**, gynecologic oncology (France); **Sabina Murshudova**, gynecologic oncology (Azerbaijan); **Alexander Mustea**, gynecologic oncology (Germany); **Eva Myriokefalitaki**, gynecologic oncology (United Kingdom); **Esten Nakken**, radiation oncology (Norway); **Eva-Maria Niine-Roolaht**, gynecologic oncology, obstetrics & gynecology (Estonia); **Esther Oliva**, pathology (United States of America); **Maja Pakiz**, gynecologic oncology (Slovenia); **Maria Abbondanza Pantaleo**, medical oncology (Italy); **Fedro Alessandro Peccatori**, medical oncology (Italy); **Nicolas Penel**, medical oncology (France); **Elisabetta Pennacchioli**, surgical oncology (Italy); **Anna Myriam Perrone**, gynecologic oncology (Italy); **Sophie Piperno-Neumann**, medical oncology (France); **Taavi Põdramägi**, surgical oncology (Estonia); **Peter Reichardt**, medical oncology (Germany); **Angeles Rovirosa**, radiation oncology (Spain); **Apostolos Sarivalasis**, medical oncology (Switzerland); **Tayup Simsek**, gynecologic oncology (Türkiye); **Shalini Singh**, radiation oncology (India); **Simona Stolnicu**, pathology (Romania); **Vladyslav Sukhin**, gynecologic oncology, obstetrics & gynecology, medical oncology, radiation oncology (Ukraine); **Joanna Szkandera**, medical oncology (Austria); **Yoshifumi Takahashi**, gynecologic oncology (Japan); **Olav Tammik**, surgical oncology (Estonia); **Cagatay Taskiran**, gynecologic oncology (Tanzania); **Maria Topalidou**, radiation oncology (Greece); **Mojca Unk**, medical oncology (Slovenia); **Koen van de Vijver**, pathology (Belgium); **Ignacio Vazquez**, medical oncology (United Kingdom); **August Vidal**, pathology (Spain); **Rohini Vinayak Kulkarni**, gynecologic

Ray-Coquard I, *et al. Int J Gynecol Cancer* 2024;0:1–23. doi: 10.1136/ijgc-2024-005823

oncology (India); **Bruno Vincenzi**, medical oncology (Italy); **Sarah Watson**, medical oncology (France); **Anneke Westermann**, medical oncology (Netherlands); **Jacek Wilczynski**, gynecologic oncology, obstetrics & gynecology (Poland); **Pauline Wimberger**, gynecologic oncology (Germany); **Kosuke Yoshihara**, gynecologic oncology (Japan); **Paolo Zola**, gynecologic oncology (Italy).

Ray-Coquard I, *et al. Int J Gynecol Cancer* 2024;0:1–23. doi: 10.1136/ijgc-2024-005823